HPV Vaccine: A Key to Cervical Cancer Elimination
Cervical cancer, a preventable and treatable disease, remains a significant global health issue, claiming around 600,000 new cases and 340,000 deaths each year. The HPV vaccine is a critical tool in combating this disease, particularly in lower-income countries where women are three times more likely to develop cervical cancer and six times more likely to die from it compared to their counterparts in wealthier nations. The stakes are high, as the World Health Organization (WHO) has set ambitious targets to eliminate cervical cancer as a public health threat by 2030.
The WHO’s 90-70-90 targets include vaccinating 90% of girls against HPV by age 15, screening 90% of women for cervical disease by ages 35 and 45, and ensuring that 90% of women with cervical disease receive treatment. Achieving these milestones could drastically reduce the incidence and mortality rates of cervical cancer, particularly in low- and middle-income countries where more than 90% of cervical cancer deaths occur.
Recent studies led by PATH have assessed the operational context and estimated the ongoing costs of HPV vaccine delivery in six countries: Ethiopia, Guyana, Rwanda, Senegal, Sri Lanka, and Uganda. These efforts are crucial as HPV vaccination typically occurs during adolescence, a time when pediatric visits are no longer routine. Rwanda stands out as a success story, having achieved vaccination coverage close to 98%, demonstrating that high vaccination rates are attainable.
Despite the progress, the challenges remain significant. The tragedy of cervical cancer is not just in its prevalence but also in the inequalities that underpin it. Women in lower-income countries face barriers to access, education, and healthcare that exacerbate their risk of developing cervical cancer. As one expert noted, “Cervical cancer should no longer be killing women,” highlighting the urgent need for action.
Furthermore, the first World Cervical Cancer Elimination Day was marked in November 2025, symbolizing a global commitment to this cause. The momentum is building, with calls for cervical cancer elimination to become a financing priority in public health agendas. The tools to combat this disease are available, and the window for action is open.
As the global health community rallies around these targets, the focus will be on increasing awareness and accessibility of the HPV vaccine. The WHO’s goals are ambitious, but with concerted efforts, they are achievable. The potential to eliminate cervical cancer as a public health threat would mark a historic milestone in cancer prevention.
Details remain unconfirmed regarding the exact strategies that will be employed to meet these targets, but the urgency for action is clear. The fight against cervical cancer is not just a health issue; it is a matter of equity and justice for women worldwide. The path forward will require collaboration, innovation, and a commitment to ensuring that no woman is left behind in the fight against cervical cancer.